Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Email me when HR 10628 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 10628. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill rewrites the timing rules that decide when a biosimilar biological product becomes eligible for Medicare price negotiations. It lets the Secretary delay a product’s inclusion on the negotiation list if the biosimilar is likely to be marketed soon, and requires rebates if the original product remains un‑negotiated after the delay. The changes aim to speed patient access to lower‑cost biosimilars while protecting Medicare’s pricing program.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 10628
3 free questions a day, no accountSponsors
- Rep. Langworthy, Nicholas A. [R-NY-23] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 10628 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 10628 freeOr ask your AI assistant about HR 10628 directly:
Add to Claude, ChatGPT or Cursor